| Literature DB >> 4510816 |
C Jacquillat, M Weil, M F Gemon, V Izrael, G Schaison, M Boiron, J Bernard.
Abstract
Fourty-four patients with acute myeloblastic leukaemia were treated with RP 22050, a new, semisynthetic derivative of daunorubicin. Complete remissions were achieved in 20 patients (45%). The median dose given was 23 mg/kg. The toxicity of RP 22050 is mainly haematological. Resistance rather than death in aplasia seemed to be the cause of failure of therapy.Entities:
Mesh：
Substances：
Year: 1972 PMID： 4510816 PMCID： PMC1786703 DOI： 10.1136/bmj.4.5838.468
Source DB: PubMed Journal: Br Med J ISSN： 0007-1447